Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Jithma P. Abeykoon(Mayo Clinic), Prashant Kapoor, Sanjay V. Patel(University Hospital Southampton NHS Foundation Trust), Kimberly Young(Bruker (United States)), Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Gabriella C. Malave(Mayo Clinic), Shaji Kumar(Mayo Clinic), Ronald S. Go(Mayo Clinic), Sikander Ailawadhi(Jacksonville College), Iuliana Vaxman(Tel Aviv University), Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), Leif Bergsagel(WinnMed), Jeremy T. Larsen(City of Hope)
Cited by 24
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k